These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 15322760)

  • 1. Pharmacokinetic studies of 9-nitrocamptothecin on intermittent and continuous schedules of administration in patients with solid tumors.
    Jung LL; Ramanathan RK; Egorin MJ; Jin R; Belani CP; Potter DM; Strychor S; Trump DL; Walko C; Fakih M; Zamboni WC
    Cancer Chemother Pharmacol; 2004 Dec; 54(6):487-96. PubMed ID: 15322760
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical and pharmacokinetic study evaluating the effect of food on the disposition of 9-nitrocamptothecin and its 9-aminocamptothecin metabolite in patients with solid tumors.
    Zamboni WC; Goel S; Iqbal T; Parise RA; Strychor S; Repinski TV; Egorin MJ; Mani S
    Cancer Chemother Pharmacol; 2006 May; 57(5):631-9. PubMed ID: 16205924
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I and pharmacologic study of intermittently administered 9-nitrocamptothecin in patients with advanced solid tumors.
    Zamboni WC; Jung LL; Egorin MJ; Potter DM; Friedland DM; Belani CP; Agarwala SS; Wong MM; Fakih M; Trump DL; Jin R; Strychor S; Vozniak M; Troetschel M; Ramanathan RK
    Clin Cancer Res; 2004 Aug; 10(15):5058-64. PubMed ID: 15297407
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Disposition of 9-nitrocamptothecin and its 9-aminocamptothecin metabolite in relation to ABC transporter genotypes.
    Zamboni WC; Ramanathan RK; McLeod HL; Mani S; Potter DM; Strychor S; Maruca LJ; King CR; Jung LL; Parise RA; Egorin MJ; Davis TA; Marsh S
    Invest New Drugs; 2006 Sep; 24(5):393-401. PubMed ID: 16505951
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of the in vivo and in vitro conversion of 9-nitro-20(S)-camptothecin to 9-amino-20(S)-camptothecin in humans, dogs, and mice.
    Hinz HR; Harris NJ; Natelson EA; Giovanella BC
    Cancer Res; 1994 Jun; 54(12):3096-100. PubMed ID: 8205523
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase I pharmacokinetics study of 9-nitrocamptothecin in patients with advanced solid tumors.
    Yan Z; Zhu Z; Li K; Chen P; Wang L; Huang C; Xue J; Liu M
    Cancer Chemother Pharmacol; 2011 Apr; 67(4):955-61. PubMed ID: 21191594
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I trial of the colloidal dispersion formulation of 9-amino-20(S)-camptothecin administered as a 72-hour continuous intravenous infusion.
    Eder JP; Supko JG; Lynch T; Bryant M; Vosburgh E; Shulman LN; Xu G; Kufe DW
    Clin Cancer Res; 1998 Feb; 4(2):317-24. PubMed ID: 9516917
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor, tissue, and plasma pharmacokinetic studies and antitumor response studies of docetaxel in combination with 9-nitrocamptothecin in mice bearing SKOV-3 human ovarian xenografts.
    Zamboni WC; Strychor S; Joseph E; Parise RA; Egorin MJ; Eiseman JL
    Cancer Chemother Pharmacol; 2008 Aug; 62(3):417-26. PubMed ID: 17957368
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral topotecan given once or twice daily for ten days: a phase I pharmacology study in adult patients with solid tumors.
    Gerrits CJ; Burris H; Schellens JH; Eckardt JR; Planting AS; van der Burg ME; Rodriguez GI; Loos WJ; van Beurden V; Hudson I; Fields S; Von Hoff DD; Verweij J
    Clin Cancer Res; 1998 May; 4(5):1153-8. PubMed ID: 9607572
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comparison of clinical pharmacodynamics of different administration schedules of oral topotecan (Hycamtin).
    Gerrits CJ; Schellens JH; Burris H; Eckardt JR; Planting AS; van der Burg ME; Rodriguez GI; Loos WJ; van Beurden V; Hudson I; Von Hoff DD; Verweij J
    Clin Cancer Res; 1999 Jan; 5(1):69-75. PubMed ID: 9918204
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase I and pharmacokinetic study of a new camptothecin derivative, 9-aminocamptothecin.
    Rubin E; Wood V; Bharti A; Trites D; Lynch C; Hurwitz S; Bartel S; Levy S; Rosowsky A; Toppmeyer D
    Clin Cancer Res; 1995 Mar; 1(3):269-76. PubMed ID: 9815982
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical pharmacokinetics of encapsulated oral 9-aminocamptothecin in plasma and saliva.
    de Jonge MJ; Verweij J; Loos WJ; Dallaire BK; Sparreboom A
    Clin Pharmacol Ther; 1999 May; 65(5):491-9. PubMed ID: 10340914
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I pharmacological and bioavailability study of oral diflomotecan (BN80915), a novel E-ring-modified camptothecin analogue in adults with solid tumors.
    Gelderblom H; Salazar R; Verweij J; Pentheroudakis G; de Jonge MJ; Devlin M; van Hooije C; Seguy F; Obach R; Pruñonosa J; Principe P; Twelves C
    Clin Cancer Res; 2003 Sep; 9(11):4101-7. PubMed ID: 14519632
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I and pharmacokinetic study of gimatecan given orally once a week for 3 of 4 weeks in patients with advanced solid tumors.
    Zhu AX; Ready N; Clark JW; Safran H; Amato A; Salem N; Pace S; He X; Zvereva N; Lynch TJ; Ryan DP; Supko JG
    Clin Cancer Res; 2009 Jan; 15(1):374-81. PubMed ID: 19118068
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I and pharmacokinetic study of triapine, a potent ribonucleotide reductase inhibitor, administered daily for five days in patients with advanced solid tumors.
    Murren J; Modiano M; Clairmont C; Lambert P; Savaraj N; Doyle T; Sznol M
    Clin Cancer Res; 2003 Sep; 9(11):4092-100. PubMed ID: 14519631
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relationship between plasma exposure of 9-nitrocamptothecin and its 9-aminocamptothecin metabolite and antitumor response in mice bearing human colon carcinoma xenografts.
    Zamboni WC; Jung LL; Egorin MJ; Hamburger DR; Joseph E; Jin R; Strychor S; Ramanathan RK; Eiseman JL
    Clin Cancer Res; 2005 Jul; 11(13):4867-74. PubMed ID: 16000585
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I trial of poly-L-glutamate camptothecin (CT-2106) administered weekly in patients with advanced solid malignancies.
    Homsi J; Simon GR; Garrett CR; Springett G; De Conti R; Chiappori AA; Munster PN; Burton MK; Stromatt S; Allievi C; Angiuli P; Eisenfeld A; Sullivan DM; Daud AI
    Clin Cancer Res; 2007 Oct; 13(19):5855-61. PubMed ID: 17908979
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I and pharmacological study of a new camptothecin derivative, exatecan mesylate (DX-8951f), infused over 30 minutes every three weeks.
    Minami H; Fujii H; Igarashi T; Itoh K; Tamanoi K; Oguma T; Sasaki Y
    Clin Cancer Res; 2001 Oct; 7(10):3056-64. PubMed ID: 11595695
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I/pharmacokinetic study of topotecan by 24-hour continuous infusion weekly.
    Haas NB; LaCreta FP; Walczak J; Hudes GR; Brennan JM; Ozols RF; O'Dwyer PJ
    Cancer Res; 1994 Mar; 54(5):1220-6. PubMed ID: 8118810
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics and bioavailability of oral 9-aminocamptothecin capsules in adult patients with solid tumors.
    Sparreboom A; de Jonge MJ; Punt CJ; Nooter K; Loos WJ; Porro MG; Verweij J
    Clin Cancer Res; 1998 Aug; 4(8):1915-9. PubMed ID: 9717819
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.